OKYO Pharma Limited (OKYO) Monday said Phase 2 study of OK-101 ophthalmic solution in patients with dry eye disease did not meet its primary goal.
However, a statistically significant improvement was observed in both a sign endpoint of total conjunctival staining and two symptoms endpoints of dry eye disease, burning/stinging and blurred vision, the company said in a statement.
According to OKYO Pharma, this first-in-human trial of OK-101 established a clear and informed path for further development in Phase 3 registration trials.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.